Ono Pharmaceutical Co., Ltd.

Ono Pharmaceuticals Co., Ltd.

Osaka University

Nipro Corporation

Hamamatsu University School of Medicine

Ono Pharmaceuticalco.,ltd.

Katsuhiko Mikoshiba

Takayuki Maruyama

Kaoru Kobayashi

Yuuki Nagao

Yoshihiko Nakai

Kousuke Tani

Toru Maruyama

Atsushi Naganawa

Tetsuji Saito

Shinsuke Hashimoto

Shuichi Ohuchida

Hiroki Okada

Nobuyuki Hamanaka

Tohru Kambe

Hideyuki Yoshida

Kazuhiko Torisu

Akio Nishiura

Nobutaka Abe

Yoshiki Sawa

Shigeru Miyagawa

Yoshiki Sakai

Shin-ichi Hamano

Shigeyuki Nonaka

Toshihiko Nagase

Masahiro Takigawa

Kazuhisa Matsuda

Satsuki Fukushima

Atsuhiro Saito

Takashi Konemura

Toshiya Kanaji

Shinsei Fujimura

Kiyoto Sakata

Hirohide Iwasaki

Kenji Kabashima

Naohiro Seo

Tetsuji Saitoh

Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.

Advanced heart failure treatment material as myocardial/cardiovascular regeneration device

Disclosed is an EP1 antagonist, particularly a compound represented by the formula (I): 

Therapeutic agent for urinary excretion disorder

Disclosed is a substance which has a low molecular weight, can be applied in a simpler manner, and has an immunopotentiating activity against cancer and/or a microorganism-mediated infectious disease. An EP4 agonist exhibits an immunopotentiating activity through the activation of a cytotoxic T cell, and is therefore useful for the prevention and/or treatment of cancer or a microorganism-mediated infection disease.

Cytotoxic T cell activator comprising EP4 agonist

A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EPagonist as an active ingredient. An EPagonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient

An N-phenylarylsulfonylamide compound of formula (I) (Ris COOH etc.; Ris hydrogen, methyl, etc.; Rand Rare a combination of methyl and methyl, etc.; Ris isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin Ereceptor, especially an EPsubtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.

N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation

(1) A preventive and/or a remedy for lower urinary tract diseases such as inflammation in the lower urinary tract, cystitis (interstitial cystitis, etc.) and urethritis; (2) an agent for improving bladder compliance and/or bladder capacity; and (3) an agent for protecting bladder mucosa and/or bladder epithelial cells and/or promoting the regeneration thereof; each containing an EPagonist. An EPagonist is useful in ameliorating symptoms of lower urinary tract diseases such as (1) frequent urination, (2) urgency of urination, (3) pain in the reproductive organs and/or lower urinary tract (for example, bladder pain, urinary tract pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain, etc.) and/or (4) discomfort in the reproductive organs and/or lower urinary tract. Among all, a selective EPagonist is useful as a preventive and/or remedy for lower urinary tract diseases having no side effect.

[object Object]

Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient

A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EPreceptor which a prostaglandin Ereceptor subtype. EPantagonist is useful for the treatment of depression, for example, endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder.

Remedies for depression containing EP1 antagonist as the active ingredient

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EPagonistic action and thus are considered useful for the prevention and/or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and/or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

8-azaprostaglandin derivatives and medical use thereof

An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).  The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and/or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

Intracellular calcium concentration increase inhibitors

An agent comprising the benzoic acid of formula (I) wherein A, B, R, Rare carbocyclic ring, heterocyclic ring, etc.; Ris hydroxy etc.; R, R, Rare alkyl etc.; R, D, E are alkylene, etc.; G is oxygen etc., as active ingredient. The compound of formula (I) is considered to be useful for the treatment and/or prophylaxis of bone diseases, cancer, systemic granuloma, immunological diseases, allergy, atopy, asthma, gumboil, gingivitis, periodontitis, neurocyte death, Alzheimer's diseases, lungs injury, pulmopathy, acute hepatitis, nephritis, myocardial ischemia, Kawasaki disease, ambustion, ulcerative colitis, Crohn's disease, multiple organ failure, sleeping disorder, platelet aggregation, etc.

Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient

Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient

The present invention provides 11,15-O-dialkyl prostaglandin E derivatives of formula (I)

11,15-O-dialkylprostaglandin E derivatives, process for producing the same, and drugs containing the same as the active ingredient

Growing community of inventors

Mishima-gun, Japan

Takayuki Maruyama